|Security||ENZN / Enzon Pharmaceuticals, Inc. (293904108)|
|Industry||Biological Products, Except Diagnostic Substances (Biotech)|
|Institutional Shares||41,691 - 0.09%|
|Common Stock Shares Outstanding||44,214,603 shares (as of 2018-06-30)|
|Institutional Value||$ 480,000 USD|
Institutional Stock Ownership and Shareholders
Enzon Pharmaceuticals, Inc. (OTC:ENZN) has 2 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41,691 shares.
Largest shareholders include
Panagora Asset Management Inc, and CT Financial Advisors LLC.
Enzon Pharmaceuticals, Inc. (OTC:ENZN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|CT Financial Advisors LLC||2,000||2,000||0.00||730||470||-35.62|
|PANAGORA ASSET MANAGEMENT INC||39,691||39,691||0.00||10||10||0.00|
Related News Stories
Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space, and also provide quick commentary on other important news, and a set of selected links to major news from the day before. (44-5)
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018. (57-6)
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (212-7)
NORWALK, Conn.--(BUSINESS WIRE)--Xerox (NYSE: XRX) today announced that, at 5:00 p.m. ET on May 13, 2018, it notified Fujifilm that the previously announced transaction agreement to combine Xerox with Fuji Xerox is being terminated in accordance with its terms due to, among other things, the failure by Fujifilm to deliver the audited financials of Fuji Xerox by April 15, 2018 and the material deviations reflected in the audited financials of Fuji Xerox, when delivered, from the unaudited financial statements of Fuji Xerox and its subsidiaries provided to Xerox prior to the date of the Subscription Agreement and taking into account other circumstances limiting the ability of the Company, Fujifilm and Fuji Xerox to consummate a transaction. (77-0)
as of ET